Baricitinib

Generic Name: Baricitinib

Brand Names: Olumiant

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₇N_₇O_₂S

CAS Number: 1187594-09-7

Unique Ingredient Identifier: ISP4442I3Y

Background: Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
...

Indication: In the US and Europe, baricitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. Baricitinib may be used as monotherapy or in combination with methotrexate or other DMARDs.
...

Associated Conditions: Alopecia Areata (AA), Coronavirus Disease 2019 (COVID‑19), Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: -

Clinical Trials

Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD

Not Applicable

Recruiting

Conditions: IgG4-related Disease With Eosinophilia

Interventions: Drug: Prednisolone
Drug: Baricitinib

First Posted Date: 2023-03-23

Last Posted Date: 2023-03-27

Lead Sponsor: Wen Zhang

Target Recruit Count: 74

Registration Number: NCT05781516

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Bejing, China

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Phase 3

Recruiting

Conditions: Areata Alopecia
Skin Diseases
Hypotrichosis
Alopecia
Hair Diseases
Pathological Conditions, Anatomical

Interventions: Drug: Placebo
Drug: Baricitinib

First Posted Date: 2023-02-10

Last Posted Date: 2024-08-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 595

Registration Number: NCT05723198

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States

and more 146 locations

Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)

Phase 2

Recruiting

Conditions: Juvenile Dermatomyositis

Interventions: Drug: Baricitinib
Biological: pharmacokinetics study
Biological: dosage of cytokines
Biological: transcriptomic analysis
Behavioral: Parent version of the Child Health Questionnaire (CHQ)
Behavioral: Childhood Health Assessment Questionnaire
Biological: Pregnancy test

First Posted Date: 2022-09-01

Last Posted Date: 2024-01-09

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 16

Registration Number: NCT05524311

Locations: 🇫🇷
Hôpital Femme Mère Enfant, Bron, France
🇫🇷
Hôpital Pellegrin, Bordeaux, France
🇫🇷
Hôpital Jeanne de Flandre, Lille, France

and more 10 locations

Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

Phase 2

Recruiting

Conditions: Immune Thrombocytopenia
ITP

Interventions: Drug: Baricitinib

First Posted Date: 2022-07-07

Last Posted Date: 2022-09-28

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 35

Registration Number: NCT05446831

Locations: 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

Baricitinib for Cutaneous Dermatomyositis

Phase 2

Withdrawn

Conditions: Dermatomyositis

Interventions: Drug: Baricitinib

First Posted Date: 2022-05-04

Last Posted Date: 2023-09-01

Lead Sponsor: University of Washington

Registration Number: NCT05361109

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

Phase 4

Conditions: Systemic Sclerosis

Interventions: Drug: Cyclophosphamide
Drug: Baricitinib

First Posted Date: 2022-03-29

Last Posted Date: 2022-03-29

Lead Sponsor: Tongji Hospital

Target Recruit Count: 60

Registration Number: NCT05300932

Locations: 🇨🇳
Department of RheumatologyTongji Hospital, Wuhan, Hubei, China
🇨🇳
Tongji Hospital, Wuhan, Hubei, China

Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

Not Applicable

Conditions: COVID-19 Severe Respiratory Failure

Interventions: Drug: Dexamethasone
Drug: Low molecular weight heparin
Drug: Tocilizumab
Drug: Anakinra 100Mg/0.67Ml Inj Syringe
Drug: Baricitinib
Drug: Dornase Alfa Inhalant Product

First Posted Date: 2022-03-15

Last Posted Date: 2022-03-15

Lead Sponsor: Democritus University of Thrace

Target Recruit Count: 150

Registration Number: NCT05279391

Locations: 🇬🇷
University Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece

Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease

Phase 2

Recruiting

Conditions: Chronic Kidney Diseases

Interventions: Drug: Placebo
Drug: Baricitinib

First Posted Date: 2022-02-14

Last Posted Date: 2024-03-21

Lead Sponsor: Duke University

Target Recruit Count: 75

Registration Number: NCT05237388

Locations: 🇺🇸
Duke Research at Pickett Road, Durham, North Carolina, United States

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial

Phase 1

Active, not recruiting

Conditions: Amyotrophic Lateral Sclerosis
Mild Cognitive Impairment
Alzheimer Disease

Interventions: Drug: Baricitinib

First Posted Date: 2022-01-12

Last Posted Date: 2024-10-04

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT05189106

Locations: 🇺🇸
Massachusetts General Hospital - ALS Site, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital - AD Site, Charlestown, Massachusetts, United States

Tocilizumab Versus Baricitinib in Patients With Severe COVID-19

Not Applicable

Completed

Conditions: COVID-19

Interventions: Drug: Tocilizumab
Drug: Baricitinib

First Posted Date: 2021-10-19

Last Posted Date: 2023-11-29

Lead Sponsor: University Hospital of Patras

Target Recruit Count: 251

Registration Number: NCT05082714

Locations: 🇬🇷
University Hospital of Patras, Department of Respiratory Medicine, Patras, Greece

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy